Extensive-stage Small Cell Lung Cancer (ES-SCLC)

DBCOND0168067NeoplasmsRespiratory Tract Diseases

Extensive-stage Small Cell Lung Cancer (ES-SCLC) is the indication for 7 drugs in DrugBank. It is covered by 13 curated, structured indications.

Also known as
Extensive Stage Small Cell Lung Cancer · Extensive-Stage Small Cell Lung Cancer · Extensive Stage Small Cell Lung Carcinoma · Extensive-Stage Small-Cell Lung Cancer · Small Cell Lung Cancer Extensive Stage
Classified under
Indicated drugs

Resolves to

Vocabularies
MedDRA10041068UMLSC0278726

What you can answer from here — as of October 23, 2026

7Indicated drugsWith each drug's targets and mechanism
Listed above
13Structured indicationsPopulation, line of therapy, route and combination as fields, not prose
Sign in
262Clinical trialsPhase, status and sponsor resolved per trial
Sign in
4Drugs reporting it as an adverse effectWith incidence where the label states it
Sign in

Which approved drugs for Extensive-stage Small Cell Lung Cancer (ES-SCLC) share a target, and which companies have late-stage candidates against it?

Answer this in Biopharma OSSign in to your account

Create a free account or log in to explore the full data card.

Create Account
Log InPaid Account Log In